All News
PsO pts not on biologics had a ⬆️ risk of PsA compared to those on biologics
⭐️HR 1.39
⭐️retrospective cohort study w/ >1300 cases
Abs#1355
#ACR21
#ACRBest
@RheumNow
https://t.co/tL37we3lwc https://t.co/SAexvn9HMb
Robert B Chao, MD doctorRBC ( View Tweet)
In PsA patients with low baseline CRP treated with IXE or ADA, a favorable reduction in pain was observed for IXE-treated
patients, irrespective of controlled or non-controlled inflammation, as
measured by CRP or SJC improvement @RheumNow #ACR21 Abst#1341 https://t.co/Nl78oASmf5 https://t.co/2qSXQr2sQS
Dr. Antoni Chan synovialjoints ( View Tweet)
To statin or not to statin?
UK cohort study 22,000 RA pts eval CV risk/diabetes w/statins
Statins:⬇️CV events by 32%, ⬆️DM-2 by 33%, ⬇️all cause mortality by 54%
NNT 102➡️prevent CV events
NNT 42➡️prevent all cause mortality
NNH 127➡️cause DM-2
absr#1427 #plenary @rheumnow https://t.co/QAt6Ie4qa7
TheDaoIndex KDAO2011 ( View Tweet)
Can’t have it all! In #RheumatoidArthritis statins when prescribed by primary care ⬇️CV mortality but sl ⬆️in type II #diabetes - just like in general pop’n-DM onset ⬆️with statins in gen pop’n #ACRBest #ACR21 @RheumNow abst#1427. https://t.co/FJ3L5w49y4
Janet Pope Janetbirdope ( View Tweet)
Abst 1128
Nelson & colleagues performed clustering analysis between collagen biomarkers and different phenotypes of multiple joint #OA
#ACR21 @RheumNow https://t.co/J9jcSUzh7M
Akhil Sood MD AkhilSoodMD ( View Tweet)
@BethIWallace on MACE risk with GC use in 26,239 veterans with RA. GC (>30 days in 6 months) associated 15% ⬆️in MACE. Abstr#1428 #ACR21 @RheumNow https://t.co/InXPiuO1GY
Richard Conway RichardPAConway ( View Tweet)
#ACR21 Abs#1428. Retrospective cohort VA study
▶️45% of patients got >30 days of GC use in a 6-month period - high # of pts!
▶️3% MACE events during study period
⭐️30 days of glucocorticoids = 15%⬆️ in odds of MACE in RA pts!
@Rheumnow https://t.co/m5bl9Ho163 https://t.co/v8hdzi1Vrb
Links:
Eric Dein ericdeinmd ( View Tweet)
Achieving MDA in PsA results in improvements in disease activity measures, PROMs and maintenance of therapy. It may help increased work productivity
and reductions in lost wages in PsA @RheumNow #ACR21 Abst#1344 https://t.co/KR1DPXt7jh https://t.co/3bfeiXxN54
Dr. Antoni Chan synovialjoints ( View Tweet)
Multinational web survey (UPLIFT) showing patients with PsA➕ active PsO associated with - more active disease; 🔼prevalence comorbidities ; depression
⭐️Positive depression screen associated with overall disease impact as measured by PsAID
Abst#1351 #ACR21 @RheumNow https://t.co/w1JETzNao9
swethaann23 swethaann23 ( View Tweet)
#ACR21 #Abstr1425 Interim AURORA2 (Extension of original RCT to 2 years) showed #lupus nephritis patients on voclosporin maintained meaningful low uPCR and stability of eGFR at 2yrs. No unexpected safety signals @RheumNow https://t.co/aclJZNOGc5 https://t.co/ENl9SzMHN3
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
How much PNL do you need with TCZ in GCA, to avoid early risks of visual loss?
GiACTA: 26w. Can we do better?
GUSTO: 3d pulse IVMP. Not enough.
Is 8w the sweet spot?🤔
sustained remission off PNL at 52w: 20/27
no visual loss/ischaemia
@MGHrheumatology #ACR21 ABST1413 @RheumNow https://t.co/IV9MorvTeW
David Liew drdavidliew ( View Tweet)
#Voclosporin still going strong in LTE in #lupus nephritis AURORA 2. No new safety signals, stable GFR. Cost may be problem! Abst#1425 #ACR21 #ACRBest @RheumNow https://t.co/biEptZbJoz
Janet Pope Janetbirdope ( View Tweet)
#ACR21 Abs#1426 - VEXAS!
Predictors of mortality:
▶️p.MetVal41 genotype (HR 3.5)
▶️Absence of ear chondritis (HR 3.8)
▶️Transfusion dependence (HR 2.6)
@Rheumnow https://t.co/m5bl9Ho163 https://t.co/LSNcF6EZHv
Links:
Eric Dein ericdeinmd ( View Tweet)
Abst1338 #acr21 @RheumNow BE ACTIVE Bimekizumab in 206 PsA:
Over half of TNFi-n pts achieved ACR50
resolution of dactylitis (70.2% NRI; 100.0% OC) & enthesitis (60.7% NRI; 80.6% OC)
PASI100 at Wks 48/152 63.3/58.7%
Low serious infect, mild/moderate candida. 1 microscopic colitis https://t.co/CJXyywZYJd
Olga Petryna DrPetryna ( View Tweet)
Abstr 1044
Anastasiou & colleagues examined Rx of inappropriate medications in elderly patients with rheumatic disease (RD)
- 40% RD patients received inappropriate meds
- Elderly living in areas of low SES likely to receive opioid Rx
#ACR21 @RheumNow #BeersCriteria https://t.co/fxBGVAtt1L
Akhil Sood MD AkhilSoodMD ( View Tweet)
#ACR21 #Abstr1426 VEXAS is only recently described but a study in 83 patients showed importance of genotyping + clinical in predicting mortality:
💠p.Met41Val (OR: 2.6)
💠Transfusion dependent (4.5)
💠Ear chondritis protective (0.3)
@RheumNow #ACRBest https://t.co/RQwONf2MJT https://t.co/VLWRGKWmQs
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
The VEXAS story developing and becoming clearer...
with high mortality genotype-phenotype linked
genotype at risk for mortality (p.Met41Val)
- smaller residual UBA1b expression
- less RP
- more fever
wonderful from @maferradastrong
#ACR21 ABST1426 @RheumNow @RP_Organization https://t.co/vELXprUrPh
David Liew drdavidliew ( View Tweet)
Voclosporin for lupus nephritis maintained reductions in proteinuria. No change in eGFR at 30 months of treatment
(AURORA 2 study)
Abs#1425
#ACR21
@RheumNow https://t.co/1y9oSVXzD8
Robert B Chao, MD doctorRBC ( View Tweet)
#ACR21 Abs#1427- Statin Use in RA
⭐️# needed to treat: 42 pts all-cause mortality
⭐️NNT 102 pts CVD events
⭐️# needed to harm: 127 pts T2DM (mild ⬆️ risk)
▶️Statin use: mortality benefit better than gen pop, CVD&DM similar effects to gen pop
@Rheumnow https://t.co/m5bl9Ho163 https://t.co/hijxbcVBzA
Links:
Eric Dein ericdeinmd ( View Tweet)
I've written more about these really useful data here for @RheumNow:
https://t.co/3dQteFr9qZ
#ACR21 @earlyarthritis @BykerkVivian https://t.co/7HufoWVtCK
Links:
David Liew drdavidliew ( View Tweet)